Review spotlights FL118 and dual cancer target degradation

FL118 is drawing fresh attention after a new review in the Journal of Experimental & Clinical Cancer Research argued that two cancer-linked proteins, DDX5 (also called p68) and UbE2T, may be especially promising therapeutic targets, and that FL118 could be an unusual way to hit both at once. The paper frames FL118 as a potential “molecular glue” degrader that can drive loss of DDX5 and, in related work from the same research group, affect UbE2T-linked pathways in difficult-to-treat solid tumors. That builds on earlier Roswell Park-led research showing FL118 directly binds and degrades DDX5, as well as a Phase 1 trial now underway in advanced pancreatic ductal adenocarcinoma and the drug’s FDA orphan designation for pancreatic cancer. (roswellpark.org)

Why it matters: For veterinary professionals, this is still firmly human oncology and still early, but it’s relevant as a signal of where translational cancer drug development is heading: toward targeted protein degradation, multi-target mechanisms, and therapies aimed at treatment-resistant disease. Comparative oncology teams, academic oncologists, and industry watchers may want to note the emphasis on pancreatic and colorectal cancers, the growing interest in molecular glues as a drug class, and the fact that FL118’s clinical development appears to be moving from preclinical mechanism work into first-in-human testing. (mdpi.com)

What to watch: Early clinical readouts from the ongoing Phase 1 pancreatic cancer study, and whether FL118’s dual-target degradation mechanism can be validated beyond preclinical and review-stage evidence. (clinicaltrials.gov)